Double-blind placebo-controlled proof of concept study with the u-receptor agonist KN203 in patients with overactive bladder syndrome Double-blind, randomized, parallel groups prospective phase II-a study for 8 weeks with two dosages of KN203 (20 and 40 mg b.i.d.) and placebo.
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2011
At a glance
- Drugs KN 203 (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 15 Jun 2011 New trial record